Travere Therapeutics

Yahoo Finance • 8 days ago

3 Stocks That May Be Undervalued By The Market In May 2026

In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings expected to grow by 17% per annum in the coming years. In this context, identifying stocks that may be undervalued by the market... Full story

Yahoo Finance • 9 days ago

3 Stocks Estimated To Be Trading Below Intrinsic Value By 11.4% To 38.4%

Over the last 7 days, the United States market has experienced a slight decline of 1.0%, yet it remains up by an impressive 23% over the past year, with earnings forecasted to grow by 17% annually. In such a fluctuating environment, identi... Full story

Yahoo Finance • 25 days ago

3 Stocks With Estimated Discounts Up To 44.8% Offering Value Opportunities

The United States market has remained flat over the last week but is up 28% over the past year, with earnings expected to grow by 16% per annum. In such a climate, identifying undervalued stocks that offer significant discounts can present... Full story

Yahoo Finance • 26 days ago

Datadog And Two Other Stocks That Could Be Trading Below Fair Value Estimates

Over the last 7 days, the United States market has remained flat, although it has experienced a notable 28% increase over the past year and earnings are forecast to grow by 16% annually. In this context of overall growth, identifying stock... Full story

Yahoo Finance • last month

Travere Therapeutics Inc. (TVTX): First-Mover Advantage Is Massive Moat

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc. (NASDAQ:TVTX) ranks 7th on this list. Investor interest in Travere Therapeutics, Inc. (NASDAQ:TVTX) has spiked since a... Full story

Yahoo Finance • last month

Stock Market Leaders Emerge In IBD 50, Rise In Volume After Follow-Through Day

Stock market leaders have emerged in the IBD 50 after the S&P 500's follow-through day, many with strong up/down volume ratios. Continue Reading... Full story

Yahoo Finance • last month

Stocks Rally on a Push for Diplomacy to End US-Iran War

The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.66%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.81%.  June E-mini S&P futures (ESM26) rose +1.18%, and June E-... Full story

Yahoo Finance • last month

Stocks Rally on US-Iran Peace Hopes and Cooler PPI Growth

The S&P 500 Index ($SPX) (SPY) today is up +0.77%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.98%.  June E-mini S&P futures (ESM26) are up +0.73%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 3 months ago

Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 19, Travere Therapeutics Inc. (NASDAQ:TVTX) released the fourth quarter earnings report. The company registe... Full story

Yahoo Finance • 3 months ago

Travere Therapeutics, Inc. (TVTX): A Bull Case Theory

We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $30.07 a... Full story

Yahoo Finance • 3 months ago

Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, highlighting significant growth for its flagship m... Full story

Yahoo Finance • 3 months ago

Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins

Earnings Call Insights: Travere Therapeutics (TVTX) Q4 2025 MANAGEMENT VIEW * CEO Eric Dube stated that "2025 was an incredible year for Travere, one that was defined by achieving a new high in the number of patients we were able to re... Full story

Yahoo Finance • 3 months ago

Is Travere Therapeutics (TVTX) Still Attractive After Recent Share Price Volatility?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. If you are wondering whether Travere Therapeutics at around US$27.82 still offers value, you are not alone, many investors... Full story

Yahoo Finance • 5 months ago

Dow Jones Futures Fall After Christmas; Nvidia Makes Big Deal

The Dow Jones set a record close and the S&P 500 hit an intraday high heading into the Christmas holiday. Palantir, Tesla, Google and Nvidia are in buy areas. Continue Reading... Full story

Yahoo Finance • 5 months ago

Dow Jones Futures Open After Market Holiday; S&P 500 At Highs

The Dow Jones set a record close and the S&P 500 hit an intraday high heading into the Christmas holiday. Palantir, Tesla, Google and Nvidia are in buy areas. Continue Reading... Full story

Yahoo Finance • 5 months ago

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

Key Points One analyst believes the company's Filspari has blockbuster potential if it earns FDA approval for a new indication. A decision on that should come very shortly.10 stocks we like better than Travere Therapeutics › The stock of... Full story

Yahoo Finance • 6 months ago

Why IBD 50's No. 2 Stock, Travere Therapeutics, Has Doubled In 2025

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, Filspari. Continue Reading View Comments... Full story

Yahoo Finance • 6 months ago

Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, Filspari. Continue Reading View Comments... Full story

Yahoo Finance • 6 months ago

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valu... Full story

Yahoo Finance • 7 months ago

Travere signals readiness for rapid FILSPARI launch in FSGS as Q3 2025 revenue hits $164.9M

Earnings Call Insights: Travere Therapeutics (TVTX) Q3 2025 MANAGEMENT VIEW * President and CEO Eric Dube emphasized "exceptional progress across our three key priorities: delivering strong commercial execution in IgA nephropathy, prep... Full story